Lyme disease is the most common tick-borne infection in both
North America and Europe. In the United States, Lyme disease is caused by
Borrelia burgdorferi, which is transmitted by the bite of the tick species
Ixodes scapularis and Ixodes pacificus. Clinical manifestations most often
involve the skin, joints, nervous system, and heart. Link to full
Approximately every 12 – 18 months following
publication, IDSA evaluates its guidelines for the need for update. Because
several years have passed since the last update, IDSA determined that a new
undertaking for Lyme disease guidelines was needed.
In order to develop
a more focused and manageable guideline than the previous guideline which had
a very broad scope, the IDSA has decided to approach this guideline topic
differently by separating the topic into distinct guidelines. This is a
practice that IDSA has implemented across many of its guidelines where the
scope has been expansive.
The first of these guideline topics to be
addressed will be on the prevention, diagnosis, and treatment of Lyme
disease. This guideline is being developed jointly with the American Academy
of Neurology and the American College of Rheumatology. Other collaborators on
the guideline include panel members from the following: American Academy of
Family Physicians (AAFP), American Academy of Pediatrics – Committee on
Infectious Diseases (AAP-COID), American Academy of Pediatrics – Section on
Emergency Medicine (AAP-EM), American College of Physicians (ACP), Association
of Medical Microbiology and Infectious Diseases – Canada (AMMI-CA), Child
Neurology Society (CNS), Pediatric Infectious Diseases Society (PIDS),
Entomological Society of America (ESA), European Society of Clinical
Microbiology and Infectious Diseases (ESCMID). Individuals from the
disciplines of cardiology, microbiology and pathology as well as a consumer
representative and a methodologist with expertise in GRADE are also among the
members of the guideline development panel.
In contrast to
the 2006 IDSA guidelines, this guideline will not provide comprehensive
coverage of Anaplasma phagocytophilum and Babesia microti outside the context
of coinfections. Those pathogens will be treated more comprehensively in
separate, forthcoming clinical guidelines.
A Project Plan has been
developed for the prevention, diagnosis, and treatment of Lyme disease and is
available from March 9 to April 24 for a 30 day Public Comment period.
Additional information can be found here.
Information on the status of these updates can be found here,
within the Practice Guidelines/Infections by Organism/Bacteria section of the